Enrofloxacin (EFX) is one of the 2nd generation quinolone antibiotics and is now widely used as a broad-spectrum antibiotic for industrial animals. Previous study showed that EFX reduces the cellular metabolic activity of spleen cells and modulates the inflammatory responses. However, little is known about its toxicity on bone marrow (BM) cells. In this study, BM cells were treated with EFX and cellular metabolic activity, cell death, the change of neutrophil (CD11b+Gr1+ cells) proportion, and antigen uptake ability of granulocytes were measured. Compared to the control, EFX-treated cells showed the decrease of cellular metabolic activity, the increase of cell death, and the decreased proportion of neutrophils. In contrast, the antigen uptake ability of granulocytes in BM cells was increased by EFX. These data suggest that EFX has only limited toxicity on BM cells. And also, EFX is safe on BM cells in a range of concentration, 6.25 – 25 μg/mL. This study can provide available data for the safety or toxicity of EFX.

Abstract
서 론
재료 및 방법
    실험동물과 약물
    골수세포의 분리와 물질처리
    골수세포의 대사활성도 측정
    유세포 분석
    통계분석
결 과
    EFX 처리에 의한 골수세포의 대사활성도 변화
    EFX 처리에 따른 cell death 변화
    표면마커 분석을 통한 호중구 비율의 변화 측정
    항원 처리를 통한 골수세포의 탐식능력 변화 측정
고 찰
REFERENCES

• Yong Han(Laboratory of Veterinary Pharmacology, College of Veterinary Medicine, Jeju National University)
• Hong-Gu Joo(Laboratory of Veterinary Pharmacology, College of Veterinary Medicine, Jeju National University/Veterinary Medical Research Institute, Jeju National University) Corresponding Author